News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Deals
Quark Pharmaceuticals Inc. Seeks Up to $20M IPO
September 27, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
San Francisco Business Times -- Quark Pharmaceuticals Inc., a developer of RNA interference drugs that signed a big deal last month with Novartis AG, wants to raise up to $20 million in the Bay Area’s latest biotech IPO.
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
Mergers & acquisitions
Lilly-Verve Proxy Filing Reveals Tumult After Departure of FDA’s Marks
June 26, 2025
·
4 min read
·
Annalee Armstrong
Deals
Longevity Biotech Takes Root on Nasdaq With $180M SPAC Deal
June 26, 2025
·
1 min read
·
Annalee Armstrong
Cardiovascular disease
Novartis Makes Potential $750M+ Bet Per Cardiovascular Disease Target in Another Flagship Pact
June 26, 2025
·
2 min read
·
Tristan Manalac
Deals
Revolution Establishes Endless Cash Runway With $2B Royalty Pharma Deal
June 24, 2025
·
1 min read
·
Annalee Armstrong
